Clinical Trial

This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-26.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT07327632
Lead Sponsor Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions Solid Tumor
Enrollment 300 participants
Start Date 2026-01-29
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-04